GRANULES Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for GRANULES from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Granules India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹600.05 |
| 52 Week High | ₹721.00 |
| 52 Week Low | ₹365.45 |
| Beta | 0.24 |
| 1 Month Change | 8.58% |
| 3 Month Change | 11.14% |
| 1 Year Change | 56.55% |
| 3 Year Change | 79.74% |
| 5 Year Change | 388.24% |
| Change since IPO | 5,661.40% |
Recent News & Updates
Recent updates
Granules India Limited's (NSE:GRANULES) Shares Not Telling The Full Story
Dec 04
Is Granules India (NSE:GRANULES) Using Too Much Debt?
Sep 16Granules India Limited (NSE:GRANULES) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 02Granules India Limited (NSE:GRANULES) Stock Rockets 27% But Many Are Still Ignoring The Company
Aug 01Granules India Limited's (NSE:GRANULES) CEO Compensation Is Looking A Bit Stretched At The Moment
Jul 31Granules India's (NSE:GRANULES) Dividend Will Be ₹1.50
Jul 17Granules India's (NSE:GRANULES) Dividend Will Be ₹1.50
Jun 19Investors Holding Back On Granules India Limited (NSE:GRANULES)
Apr 08Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next
Jan 26Many Still Looking Away From Granules India Limited (NSE:GRANULES)
Dec 28Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Nov 13A Look At The Fair Value Of Granules India Limited (NSE:GRANULES)
Oct 24Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
May 19Should You Be Adding Granules India (NSE:GRANULES) To Your Watchlist Today?
Mar 29Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Jan 19Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
Oct 01Estimating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Aug 18Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.75
Jul 14Is Granules India (NSE:GRANULES) A Risky Investment?
Jun 28Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.75
Jun 09Estimating The Fair Value Of Granules India Limited (NSE:GRANULES)
May 06Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.25
Feb 10Calculating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Feb 02Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching
Jan 20These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Dec 21Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock
Aug 18Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25
Aug 03Is Granules India (NSE:GRANULES) Using Too Much Debt?
Jun 11Shareholder Returns
| GRANULES | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.8% | -0.2% | -1.9% |
| 1Y | 56.5% | 43.4% | 24.7% |
Return vs Industry: GRANULES exceeded the Indian Pharmaceuticals industry which returned 43.4% over the past year.
Return vs Market: GRANULES exceeded the Indian Market which returned 24.7% over the past year.
Price Volatility
| GRANULES volatility | |
|---|---|
| GRANULES Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: GRANULES has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GRANULES's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 4,057 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology.
Granules India Limited Fundamentals Summary
| GRANULES fundamental statistics | |
|---|---|
| Market cap | ₹145.47b |
| Earnings (TTM) | ₹4.87b |
| Revenue (TTM) | ₹44.78b |
29.9x
P/E Ratio3.2x
P/S RatioIs GRANULES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRANULES income statement (TTM) | |
|---|---|
| Revenue | ₹44.78b |
| Cost of Revenue | ₹19.28b |
| Gross Profit | ₹25.50b |
| Other Expenses | ₹20.63b |
| Earnings | ₹4.87b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.10 |
| Gross Margin | 56.94% |
| Net Profit Margin | 10.88% |
| Debt/Equity Ratio | 29.5% |
How did GRANULES perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield9%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 21:47 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Granules India Limited is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| Cyndrella Carvalho | Centrum Broking Limited |
| Rashmi Sancheti Shetty | CGS International |